We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.16B
AUM Growth
+$73.7M
Cap. Flow
+$24.1M
Cap. Flow %
2.08%
Top 10 Hldgs %
27.51%
Holding
208
New
17
Increased
35
Reduced
30
Closed
120

Sector Composition

Rank Sector Weight
1 Healthcare 90.35%
2 Industrials 4.01%
3 Technology 0.1%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$51M 4.39%
600,242
+68,447
+13% +$3.46M
PPD
2
DELISTED
PPD, Inc. Common Stock
PPD
$35.6M 3.06%
963,054
+190,665
+25% +$6.04M
LH icon
3
Labcorp
LH
$24.3B
$32.9M 2.83%
203,248
+185,904
+1,072% +$29.5M
PTCT icon
4
PTC Therapeutics
PTCT
$6.48B
$31.3M 2.69%
669,578
+148,911
+29% +$7.33M
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
$30.7M 2.64%
409,905
+47,005
+13% +$3.13M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$30.4M 2.61%
2,153,633
+402,720
+23% +$5.87M
ATRC icon
7
AtriCure
ATRC
$1.7B
$28.3M 2.43%
708,717
+294,164
+71% +$12.5M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$27.3M 2.35%
294,733
+4,150
+1% +$320K
RCM
9
DELISTED
R1 RCM Inc. Common Stock
RCM
$26.4M 2.27%
1,540,393
-103,416
-6% -$1.51M
SILK
10
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$26.1M 2.24%
387,983
-134,245
-26% -$7.33M
EVH icon
11
Evolent Health
EVH
$480M
$25.9M 2.23%
2,086,435
+264,138
+14% +$3.11M
TDOC icon
12
Teladoc Health
TDOC
$1.6B
$25.5M 2.19%
116,339
-1,949
-2% -$413K
TNDM icon
13
Tandem Diabetes Care
TNDM
$1.18B
$25.3M 2.18%
222,968
+25,954
+13% +$2.73M
TFX icon
14
Teleflex
TFX
$5.85B
$24.7M 2.12%
72,518
+16,070
+28% +$5.95M
IRTC icon
15
iRhythm Holdings
IRTC
$3.59B
$24.7M 2.12%
103,565
-12,330
-11% -$2.18M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.23B
$23M 1.97%
556,514
+213,851
+62% +$9.23M
CNC icon
17
Centene
CNC
$31.2B
$22.8M 1.96%
390,090
-11,068
-3% -$688K
RVMD icon
18
Revolution Medicines
RVMD
$40.3B
$22M 1.89%
+633,090
New +$17.5M
APRE icon
19
Aprea Therapeutics
APRE
$7.86M
$22M 1.89%
45,784
TPTX
20
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$21.9M 1.88%
250,481
-34,005
-12% -$2.37M
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$21.3M 1.84%
416,059
+191,700
+85% +$9.39M
EXEL icon
22
Exelixis
EXEL
$14B
$20.9M 1.8%
856,770
-100,624
-11% -$2.35M
DXCM icon
23
DexCom
DXCM
$27.5B
$20M 1.72%
193,652
+16,800
+9% +$1.76M
HMSY
24
DELISTED
HMS Holdings Corp.
HMSY
$18.7M 1.61%
782,563
+221,002
+39% +$6.5M
ZNTL icon
25
Zentalis Pharmaceuticals
ZNTL
$311M
$18.2M 1.56%
556,712
+412,512
+286% +$14.4M

Similar funds

Sectoral Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sectoral Asset Management held 208 positions worth $1.16B, up 6.8% from $1.09B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Sectoral Asset Management's Q3 2020 filing shows 17 new, 35 increased, 30 reduced and 120 closed positions. Its largest new stake was Arcus Biosciences: 922,800 shares worth $15.8M. The largest sale was HILL-ROM HOLDINGS, INC., an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Industrials and Technology.

  • Sectoral Asset Management's largest Q3 2020 buy was Arcus Biosciences: 922,800 shares worth $15.8M.
  • Sectoral Asset Management added most to Labcorp in Q3 2020, an estimated $29.5M increase.
  • Sectoral Asset Management's biggest Q3 2020 reduction was Change Healthcare Inc. Common Stock, cutting an estimated $17.1M.
  • Sectoral Asset Management fully exited HILL-ROM HOLDINGS, INC. in Q3 2020, selling an estimated $27.4M.
  • Sectoral Asset Management's ten largest holdings make up 28% of its $1.16B portfolio in Q3 2020.
  • Sectoral Asset Management opened 17 new positions and closed 120 in Q3 2020.
  • Sectoral Asset Management's portfolio value rose 6.8% quarter-over-quarter to $1.16B.

Based on Sectoral Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.